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Background: Ginsenoside Rg3 and arginineefructose (Arg-Fru) are known as the hypotensive com-
pounds of Panax ginseng; however, their efﬁcacy on antihypertension has not been reported yet to our
best knowledge. Thus, hypotensive components-enriched fraction of red ginseng (HCEF-RG) was pre-
pared from ﬁne root concentrate (FR) and their antihypertensive effects were investigated in sponta-
neously hypertensive rats (SHR).
Methods: Male SHRs were divided into six groups: control (Wistar Kyoto, SHR); FR 500; FR 1,000; HCEF-
RG 500; and HCEF-RG 1,000; samples (mg/kg body weight) were orally administered every day for 8 wk.
Blood pressure was monitored at 1 wk, 2 wk, 3 wk, 4 wk, 6 wk, and 8 wk by tail cuff method. At 8 wk
after samples administration, mice were killed for the measurement of renin activity (RA), angiotensin-I
converting enzyme inhibition, angiotensin II, and nitric oxide (NO) levels in plasma.
Results: HCEF-RG with four-fold more Rg3 and 24-fold more Arg-Fru contents was successfully prepared
from reacted mixtures of FR and persimmon vinegar (12 times against FR, v/v) at 80C for 18 h. Both FR
1,000 and HCEF-RG 1,000 showed lowered systolic blood pressure than SHR control group and HCEF-RG
1,000 group exhibited a signiﬁcant decrease in diastolic blood pressure. RA was signiﬁcantly lowered in
all treated groups, while angiotensin II did not affect by FR and HCEF-RG treatment. However,
angiotensin-I converting enzyme inhibition and NO in FR 1,000 and HCEF-RG 1,000 were signiﬁcantly
increased compared with SHR control group.
Conclusion: HCEF-RG is more effective and useful for alleviating hypertension than FR, implying the
health beneﬁt of Rg3 and Arg-Fru.
Copyright  2015, The Korean Society of Ginseng, Published by Elsevier. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The incidence of various age-related degenerative neurological
and cardiovascular diseases continues to increase signiﬁcantly as
lifestyles change and the population ages. Hypertension is charac-
terized by an increase in arterial blood pressure due to increased
cardiac output or peripheral vasoconstriction. The incidence of
hypertension as a disease is low; however, this disorder has been
strongly associated with stroke, myocardial infarction, diabetes,
and heart failure. Hypertension also leads to cardiac and vascular
muscle hypertrophy, as well as arteriosclerosis [1]. The vascular
complications of hypertension are exacerbated by concomitantutrition, Hanyang University, 222,
).
ht  2015, The Korean Society of G
d/4.0/).vascular injuries such as hyperlipidemia or hyperglycemia, which
are attributable to cell characteristics, expression of autocrine or
paracrine growth hormones, and changes in growth hormone re-
ceptors [2].
Clinically, hypertension is deﬁned as a condition in which the
systolic blood pressure exceeds 120 mmHg and the diastolic pres-
sure exceeds 80 mmHg. Blood pressure is mainly modulated by the
renineangiotensin systems (RAS) and the vasopressin system.
Angiotensin-converting enzyme (ACE), which plays a key role in
the RAS, converts angiotensin I to angiotensin II and the dipeptide
histidineeleucine. To treat hypertension, ACE inhibitors such as
enalapril, captopril, ramipril, and lisinopril have been developedWangsimni-ro, Seongdong-gu, Seoul 04763, Korea.
inseng, Published by Elsevier. This is an open access article under the CC BY-NC-ND
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effects such as changes in taste, leukopenia, vascular edema, liver
function abnormalities, and dry cough [3]. New antihypertensive
drugs with established efﬁcacy and safety are necessary to improve
treatment regimens for patients that suffer from hypertension.
Various in vitro and in vivo studies have examined the antihyper-
tensive activities of different plants such as Gastrodia elata [4],
Alisma canaliculatum [5], and Monascus [6].
The persimmon tree (Diospyros kaki) produces fruits in the fall
season; as described in Oriental medicine, the fruits are charac-
terized by a sweet and refreshing taste, with no poisonous sub-
stances. In particular, a colloidal ﬂuid from unripe persimmon fruits
has been used for treating hypertension [7]. In Japan, persimmon
juice has been traditionally used to treat hypertension and prevent
heart attacks [8]. The hypotensive effect of Panax ginseng is
attributable to the saponin, ginsenoside Rg3, which could be con-
verted by acidic hydrolysis from protopanaxadiol-type saponins
and exhibits protective effects against hypertension [9e14].
Furthermore, arginineefructose (Arg-Fru) produced from argi-
nineefructoseeglucose (Arg-Fru-Glc) by the Maillard reaction un-
der acidic condition is known to be a speciﬁc active compound in
Korean Red Ginseng [15]. Arg-Fru is absorbed into the small in-
testine after release from Arg-Fru-Glc by maltase and then partic-
ipates in the nitric oxide (NO)-mediated vasodilation [16].
Therefore, if ginsenoside Rg3-Arg-Fru-enrichment materials can be
produced, they will be useful in alleviating hypertension and
consequently allowing the food industry to develop new hypo-
tensive compounds-fortiﬁed products. Thus, in this study, we pre-
pared a hypotensive components-enriched fraction from red
ginseng (HCEF-RG) under various conditions with persimmon
vinegar and evaluated the ability of HCEF-RG to improve the hy-
pertension in spontaneously hypertensive rats (SHR).
2. Materials and methods
2.1. Materials
The red ginseng tail root (4-year-old, 2010) was provided by
Cheon Ji Yang (Seoul, Korea) and Korean persimmon vinegar (pH
3.6) was purchased from Nong Hyup (Wanju, Korea). Other re-
agents were purchased from SigmaeAldrich (St. Louis, MO, USA).
2.2. Preparation of HCEF-RG
The antihypertensive fractions with enriched ginsenoside Rg3
were made by modifying a method described by Ko et al [13]. To
obtain the ﬁne root concentrates (FR), red ginseng tail root (10 kg)
was added to 70% ethanol (100 L, v/w) and extracted at 60 2C for
8 h. The extracts were centrifuged at 2,250g for 30 min and the
supernatant was collected and then concentrated in a rotary
evaporator at 60C. FR was subjected to the preparation for anti-
hypertensive fractions by mixing with persimmon vinegar (12
times, v/v) and then reacting in a water bath (WEB Multi-purpose
Extraction Water Bath, Daihan, Korea) with a reﬂux condenser at
70C, 80C, and 90C for 3 h, 6 h, 12 h, 18 h, 24 h, and 48 h.
2.3. Ginsenoside analysis by HPLC
Sep-Pak C18 cartridge (Waters, Milford, MA, USA) was used to
pretreat the sample and then a C18 cartridge with 5 mL of 100%
methanol and 15 mL of distilled water was gradually activated. The
resulting samples (5 mL) were loaded onto the C18 cartridge, and
gradually washed thoroughly with 15 mL of distilled water and
20 mL of 30% methanol. Next, crude saponinwas used to rinse with
5 mL of 100% methanol. The fractions were ﬁltered by a 0.22-mmmembrane ﬁlter and the ﬁltering fractions from methanol and
distilled water were used for ginsenoside and Arg-Fru, respectively.
The Waters 486 Tunable Absorbance Detector HPLC system
(Waters) equipped with an YMC-Pack Pro C18 column
(4.6 mm  250 mm, 5 mm; Waters) was used for ginsenoside sep-
aration. The detection wavelength was set at 203 nm and the sol-
vent ﬂow rate was held constant at 1.6 mL/min and the
temperature of the columnwas set at 45C. The mobile phase used
for the separation consisted of solvent A (acetonitrile) and solvent B
(water). A gradient elution procedure was used at 0 min, 15%; 0e
14 min, 15e20%; 14e17 min, 20e39%; 17e57 min, 39e48%; 57e
70min, 48e70%; 70e80min, 70e100%; 80e120min,100e60%; and
120e130 min, 60e15%. The injection volume was 20 mL. Standard
ginsenoside materials (Embo Laboratory, Daejeon, Korea) were
prepared in HPLC-grade methanol.
For the analysis of Arg-Fru, the Amperometric Detector HPLC
system (Waters) equipped with an CarboPac PA-1 column
(4 mm  250 mm, 5 mm; Waters) was used. The solvent ﬂow rate
with the isocratic mobile phase (water: 250mMNaOH¼ 50:50, v/v)
was held constant at 1.0 mL/min and the temperature of the col-
umn was set at 30C. The injection volume was 5 mL and the
working and reference electrodewere Au and Ag/AgCl, respectively.
2.4. Animals and diets
The experiment was performed using 8-wk-old male Wistar
Kyoto rats (WKY; normal group, male, 130e175 g body weight;
Charles River Co., Kanawa, Japan) and SHR (hypertension group,
male, 180e215 g body weight, Orient Bio Co. Ltd., Seoul, Korea). The
animals were allowed to acclimate for a wk and then randomly
divided into six groups (n ¼ 8 each): WKY-control; SHR-control;
SHR- FR 500; SHR- FR 1,000; SHR- HCEF-RG 500; and SHR- HCEF-RG
1,000. The animals were housed individually in stainless steel cages
arranged in a randomized complete block design at a temperature of
231C and humidity of 53 2% in a light-controlled roomunder a
12 h lightedark cycle. The animals had access to food (18% protein,
2018S; Harlan Laboratories Inc., Indianapolis, IN, USA) and water ad
libitum. The control groups (WKY, SHR) were provided with sterile
distilled water, and the other groups (FR, HCEF-RG) were given
forced oral administration (500 mg/kg, 1,000 mg/kg bodyweight)
using a disposable syringe for 8 wk. The weight and dietary intake
were measured once per wk. At the end of the experimental period,
the animals were anesthetized with isoﬂurane, nitrogen, and oxy-
gen withholding food for 12 h, and blood samples were taken from
the inferior vena cava to determine the levels of plasma biomarkers.
The blood sample was centrifuged in a tube with EDTA coating at
1,006g for 10 min to remove plasma, and the resulting sample was
stored at80C before analysis. The care and treatment of rats were
approved by theWoojung Life Science Research Center Animal Care
Committee (Suwon-si, Gyeonggi-do, Korea) (WJIACUC110818-03-
04), and the procedures were in accordance with the Korean Guide
for the Care and Use of Laboratory Animals.
2.5. Heart rate and blood pressure
Heart rate, systolic blood pressure, and diastolic blood pressure
were measured at 1 wk, 2 wk, 3 wk, 4 wk, 6 wk, and 8 wk by
electrosphygmomanometer (Letica LE 5002; Panlab, Barcelona,
Spain). After stabilization for 15 min at 37C in a mold, blood
pressure was measured by the tail cuff method.
2.6. Renin activity
The plasma (200 mL) was added to 200 mL of precooled enzy-
matic inhibitor and was divided into two equal volumes of 200 mL
Table 1
Ginsenoside contents in the hypotensive fractions from ﬁne root concentrates treated with persimmon vinegar at various temperature and time1)
Temp (C) Time (h) Ginsenoside (mg/g)
Rb1 Rb2 Rc Rd Rf Rg3 Rh2 Total
No treatment 11.37  0.61a 5.58  1.48a 10.52  1.13a 3.70  0.57a 2.00  0.41a 2.72  0.40j 5.88  0.63f 40.96  4.09a
70 3 10.01  0.45b 3.66  0.18b 9.11  0.41b 3.06  0.09b 1.66  0.11b 3.73  0.21i 6.24  0.88f 37.49  1.90a
6 9.56  0.66b 3.28  0.25bc 8.19  0.19c 2.98  0.65bc 1.67  0.77b 4.89  0.12h 6.88  0.87f 37.47  1.30a
12 7.91  0.55d 2.70  0.17cd 6.24  0.42d 2.76  0.03c 1.68  0.07b 6.57  0.13f 10.00  0.78d 37.88  1.75a
18 6.27  0.32e 2.13  0.24de 4.35  0.44e 2.46  0.07d 1.57  0.06bc 8.18  0.47e 9.86  1.16d 34.84  1.51b
24 4.51  0.27f 1.25  0.37f 2.93  0.32f 1.99  0.09e 1.35  0.06cd 8.94  0.16d 10.74  0.36d 31.73  0.72cd
48 2.22  0.08gh 0.32  0.01g 0.65  0.03h 1.22  0.03g 1.22  0.10de 11.27  0.30a 14.45  0.59a 31.36  0.92cd
80 3 8.62  0.79c 3.05  0.29bc 6.57  0.42d 2.95  0.11bc 1.70  0.11b 5.87  0.11g 8.57  0.51e 37.35  1.45a
6 6.27  0.33e 1.94  0.10e 4.09  0.34e 2.33  0.06d 1.71  0.17b 7.85  0.11l 10.36  0.55d 34.57  0.24b
12 3.93  0.23f 0.99  0.14f 2.02  0.78g 1.73  0.08f 1.51  0.10bc 9.59  0.27c 13.30  0.71b 33.09  0.85bc
18 2.02  0.27gh 0.07  0.06g 0.33  0.02h 0.88  0.35h 1.02  0.09ef 11.51  0.60a 14.57  0.31a 30.43  0.52d
24 1.71  0.22gh 0.00  0.00g 0.00  0.00h 0.55  0.03i 0.84  0.13f 10.79  0.38b 12.84  0.23bc 26.74  0.91e
48 0.52  0.20i 0.00  0.00g 0.00  0.00h 0.00  0.00j 0.11  0.10g 2.96  0.09j 3.51  0.01g 7.12  0.16f
90 3 0.45  0.05f 1.08  0.08f 2.01  0.25g 1.88  0.13ef 1.49  0.09bc 8.86  0.18d 10.71  0.18d 30.57  0.38cd
6 2.33  0.23g 0.00  0.00g 0.00  0.00h 0.93  0.03h 2.48  0.15bc 11.36  0.71a 15.44  0.94a 31.55  1.51cd
12 1.68  0.06h 0.00  0.00g 0.00  0.00h 0.00  0.00j 0.93  0.05f 9.97  0.13c 11.93  1.00c 24.53  1.03e
18 0.63  0.02i 0.00  0.00g 0.00  0.00h 0.00  0.00j 0.12  0.11g 2.90  0.04j 3.62  0.08g 7.29  0.12f
24 0.63  0.09i 0.00  0.00g 0.00  0.00h 0.00  0.00j 0.04  0.07g 3.16  0.16j 4.20  0.39g 8.04  0.49f
48 0.16  0.14i 0.00  0.00g 0.00  0.00h 0.00  0.00j 0.00  0.00g 2.70  0.11j 3.84  0.30g 6.71  0.29f
Data are presented as mean  SD.
1) Values with different superscripts within the same column are signiﬁcantly different among samples at a ¼ 0.05 level by Duncan’s multiple range test.
K.H. Lee et al / Antihypertensive effect of Rg3 239each. Then the mixture was allowed to react for 1 h at 37C and
another mixture was allowed to react for 1 h at 4C. Both mixtures
(75 mL) were added to antibody coated tube and 100 mL of antigen
125I solutionwas added to the antibody coated tube containing each
mixture. Then the resulting solution was put in a shaking water
bath (280 rpm) at 25C for 2 h. Plasma renin activity was calculated
using 1470 WIZARD automatic gamma which was determined by
counting the radioactivity (cpm) for 1 min.
2.7. Inhibitory activity of ACE
Sodium borate buffer (50mM) containing 100 mL of plasma and
300mM of NaCl was added to the 400 mL (hippuryl-L-histidyl-L-
leucine, 7mM) of substrate and incubated for 30 min in 37C and
was then added to 500 mL of 1N HCl. The resulting solution was
mixed with 3 mL of ethyl acetate, vortexed strongly for 60 s, and
centrifuged at 11178g for 5 min. The supernatant (1 mL) was
evaporated on an 80C heating block, 500 mL of distilled water was
added, and then the absorbance was read at 228 nm.
2.8. Angiotensin II levels
The plasma angiotensin II levels were measured using ELISA kit
EA3501-1 (Assaypro, St Charles, MO, USA). The plasma sample
(25 mL) was added to the plate coated with angiotensin II antibody,
25 mL of biotinylated angiotensin II solution was directly added to
the plate, and then incubated for 2 h. After washing with 200 mL of
wash buffer, the buffer was removed using a paper towel and the
resulting contents were incubated with 50 mL of streptavidine
peroxidase conjugate for 50 min at room temperature. After adding
50 mL of chromogen substrate, they were incubated for 10 min and
then the absorbance was read at 450 nm.
2.9. Nitric oxide concentration
The amount of nitrite in the supernatant was measured using a
commercially available NO detection kit (iNtRON biotechnology,
Seongnam, Korea). After ﬁltering plasma through a 0.22 mm-size
ﬁlter, 100 mL of N1 buffer was added to each well, and the plate was
incubated at room temperature for 10 min. N2 buffer was thenadded and the plate was incubated at room temperature for 10min.
The absorbance of the content of each well was measured at
540 nm using a Sunrise absorbance reader (TECAN, Salzburg,
Austria).
2.10. Statistical analysis
All experiments were performed in triplicate and the data are
represented as the mean  standard deviation. The signiﬁcance of
differences (p < 0.05) among the corresponding mean values was
determined using one-way analysis of variance (ANOVA) followed
by Duncan’s multiple comparison test or Student t test (SPSS,
version 17.0; SPSS Inc., Chicago, IL, USA).
3. Results and discussion
3.1. HCEF-RG preparation
The contents of ginsenosides in the antihypertensive fractions
prepared by various reaction conditions were investigated, as
presented in Table 1. The contents of protopanaxadiol-type ginse-
nosides (Rb1, Rb2, Rc, and Rd) decreased with increasing reaction
temperature and time. Furthermore, Rb2, Rc, and Rd were dis-
appeared after 24 h and 6 h reaction time at 80C and 90C,
respectively. Among protopanaxatriol groups, Rf contents
decreased but the amounts of Rg3 and Rh2 increased with
increasing reaction temperature and time. Moreover, Rg3 and Rh2
were signiﬁcantly lowered after 24 h and 12 h reaction time at 80C
and 90C, respectively. Even though there were the changes in the
contents of each ginsenoside by treatment conditions, total ginse-
noside levels decreased after treatment. However, the main
concern in this study was the fortiﬁcation of Rg3 contents as a
hypotensive component. As can be seen in Fig. 1, the changes of Rb1
and Rdwere closely related to formation of Rg3. The contents of Rb1
and Rd showed a time-dependent decrease at three temperatures,
while Rg3 contents increased over time except at 90C. Further-
more, the maximum Rg3 level was observed at 48 h at 70C, 18 h at
80C, and 6 h at 90C. Kim et al [17] reported that Rb1 was con-
verted to Rg3 when heat and acid treatments were administered
concomitantly. At constant time and heat treatment at 0e130C,
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J Ginseng Res 2016;40:237e244240the contents of Rc, Rd, and Re increased, although even these
decreased at 105C; however, the concentration of Rg2 and Rg3
increased with temperature. In addition, when ginseng root was
treated at 37C, 60C, and 80C using various acids including acetic
acid, citric acid, lactic acid, tartaric acid, and HCl, Rg3 contents
increased in all the treated groups, except for the 80C HCl group.
Treatment at 60C with citric acid for 5 h resulted in a 3.6-fold
increase in Rg3 content [12].
In Fig. 2, the contents of Arg-Fru-Glc decreased with increasing
reaction temperature and time as comparedwith the control, while
Arg-Fru increased as compared with control. Specially, Arg-Fru was
fully released fromArg-Fru-Glc under acidic condition at 70C for 3h
and at 80C for 18 h, indicating 24-foldmore levels than the control.
Therefore, in this study, we determined the reaction condition of
18 h at 80C with 12 times the amount of persimmon vinegar for
Rg3 and Arg-Fru formation for enhancing hypotensive component
in red ginseng considering the efﬁciency of reaction temperature
and time. Then, HCEF-RG was compared for antihypertensive ef-
fects of FR using an SHR animal model system.F
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Fig. 2. (A) Contents of arginineefructoseeglucose (Arg-Fru-Glc) and (B) argininee
fructose (Arg-Fru) in ﬁne root concentrates treated with persimmon vinegar at various
temperature and time. Data are expressed as mean  SD. Values with different su-
perscripts in the same bar are signiﬁcantly different among samples at a ¼ 0.05 level
by Duncan’s multiple range test.3.2. Heart rate and blood pressure
Fig. 3 shows the effect of the FR or HCEF-RG treatment, taken for
8 wk, on heart rate and systolic and diastolic blood pressure in SHR.
The heart rate decreased in all of the groups after the 1st wk and
then did not change from the range of 400e450 beats/min. The
systolic blood pressure of all groups gradually increased until Week
4 and then decreased. After 8 wk of the study, the rats fed FR or
HCEF-RG at 1,000 mg/kg body weight had signiﬁcantly (p < 0.05)
lower systolic blood pressure than the control group. The FR 500
group had a signiﬁcantly greater decrease compared to the SHR
control group after 2 wk but increased after 3 wk and signiﬁcantly
(p < 0.05) decreased until the 4e6 wk period. The last wk (Week 8)
of the study indicated increased systolic blood pressure in the rats.
The FR 1,000 group had signiﬁcantly (p< 0.05) lower systolic blood
pressure than the SHR control group for 8 wk and the decreased
ratio of systolic blood pressure was 7% compared with the SHR
control group. The systolic blood pressure remained signiﬁcantly
(p < 0.05) lower in the HCEF-RG 500 group compared to the SHR
controls during the 6 wk, but increased after 8 wk. The systolic
blood pressure remained signiﬁcantly (p< 0.05) lower in the HCEF-
RG 1,000 group compared to the SHR controls during the wk 4e8,
and caused a progressive decrease in systolic blood pressure that
was about 17% of the decrease ratio. As a result, the HCEF-RG
1,000 mg/kg body weight sample showed a stronger effect ofdecreased blood pressure compared with the other samples. All
groups indicated an increase in diastolic blood pressure and a
decrease after 4 wk. The HCEF-RG 1,000 group had signiﬁcantly
(p < 0.05) lower diastolic blood pressure than the SHR control
group after 8 wk. The FR groups with 500 mg/kg and 1,000 mg/kg
body weight samples had signiﬁcantly lower diastolic blood
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Fig. 3. (A) Changes of heart rate, (B) systolic blood pressure, and (C) diastolic blood
pressure in spontaneously hypertensive rats (SHRs) treated with ﬁne root concentrate
(FR) and hypotensive component-enriched fraction of red ginseng (HCEF-RG) for 8 wk
(SHR-control, 6; FR500,B; FR1,000,C; HCEF-RG500,,; HCEF-RG1,000, -). Wistar
Kyoto (WKY)-control (normal control): WKY provided with sterile distilled water;
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groups (hypertension and FR treatment): SHR orally provided with ﬁne root concen-
trations (500 mg/kg, 1,000 mg/kg body weight); HCEF-RG groups (hypertension and
HCEF-RG treatment): SHR orally provided with hypotensive components-enriched
fraction of red ginseng (500 mg/kg, 1,000 mg/kg body weight). Data are expressed as
mean  SD, n ¼ 8. *p < 0.05 compared with SHR-control.
K.H. Lee et al / Antihypertensive effect of Rg3 241pressure than the SHR controls after 4e6 wk. The HCEF-RG 500
group had signiﬁcantly (p < 0.05) lower diastolic blood pressure
than the SHR control group for 6 wk. The HCEF-RG 1,000 group had
signiﬁcantly (p < 0.05) lower diastolic blood pressure than the SHR
control group for 2e6 wk. However, after 8 wk of study, the dia-
stolic blood pressure was not signiﬁcantly (p < 0.05) different. Theresults indicate that the magnitude of the diastolic blood pressure
response of the HCEF-RG 1,000 mg/kg body weight group was
signiﬁcantly (p < 0.05) decreased compared to the SHR control
group after 8 wk of study. The diastolic blood pressure was
149.2  33.6 mmHg and the decrease ratio of the diastolic blood
pressure was 11% compared with the SHR control group. In
conclusion, the HCEF-RG 1,000 mg/kg body weight sample showed
a decrease in blood pressure compared with the other samples.
The earlier report showed that rats that received powder from
Korean Red Ginseng had signiﬁcantly (p < 0.05) lower blood pres-
sure than the control group for 1e2months [18], and that the crude
saponin extracted from Korean Red Ginseng of 50 mg/kg and
100mg/kgbodyweight of SHRdecreased the systolic bloodpressure
(6% and 36%, respectively). After taking a capsule of Korea red
ginseng, 0.5 g for 180 min, the patients with hypertension had
signiﬁcantly (p < 0.05) lower diastolic blood pressure than the
placebo group. Additionally, Rg3-enriched red ginsenghas also been
reported to play an important role in decreasing blood pressure [19].
Total saponins and Rg3 are also involved in vasodilation; the
mechanism is associatedwith the release of NO and the activation of
Ca2þ-dependent Kþ channels in vascular smooth muscles [20].
Previous studies have demonstrated that an 8e9% decrease in blood
pressuremay induce a 21% decrease in heart attacks, aswell as a 37%
reduction in stroke [21]. In the present study, HCEF-RG of 1,000mg/
kg was administered to SHR, which is equivalent to a daily Rg3
intake of 4.04mg. After 8wk of treatment, a 17% decrease in systolic
blood pressure, as well as an 11% reduction in diastolic blood pres-
sure was observed. This response may be attributable to the Rg3/
Arg-Fru-mediated NO release from vascular endothelial cells.
3.3. Renin activity, ACE, and angiotensin II
As can be seen in Fig. 4A, all samples had signiﬁcantly lower
renin activity than the SHR control group (p < 0.05). The FR and
HCEF-RG groups had decreased levels when compared with the
SHR controls. However, there were no signiﬁcant differences in the
concentration of samples between the FR and HCEF-RG groups and
the SHR control group. In case of ACE-inhibiting activity (Fig. 4B),
the FR and HCEF-RG groups had signiﬁcantly decreased levels
when compared with the SHR controls (p < 0.05); HCEF-RG 500
group (8% reduction)/ FR 500 group (17% reduction)/ FR 1,000
group (25% reduction) / HCEF-RG 1,000 group (29% reduction).
Moreover, angiotensin II levels were dose-dependently reduced in
the FR and HCEF-RG groups when compared to the SHR control
groups (p < 0.05; Fig. 4C).
Several clinical results have shown that ACE-inhibiting sub-
stances not only directly inhibit hypertension by suppressing the
activation of ACE but also effectively decrease chronic renal disease,
arteriosclerosis, heart attack, and associated death [22,23]. Kim et al
[24] reported the ACE-inhibitory effects of ginseng in Korean
traditional rice wine. Rg3 has been shown to inhibit the activation
of ACE, thus contributing to the prevention of hypertension [25].
The Rg3 content in FR and HCEF-RG and the concentration-
dependent effects of ACE inhibition were conﬁrmed in this study;
Rg3 enrichment further promoted ACE inhibition. In the case of the
HCEF-RG 1,000 mg/kg group, which showed a 29% ACE inhibiting
activity compared to the SHR control, a 16% inhibiting activity was
observed for angiotensin II. These ﬁndings show that HCEF-RG
1,000 mg/kg acts on the overall hypotensive mechanism by
decreasing renin activation, ACE, and angiotensin II in the RAS.
3.4. Nitric oxide production
Fig. 5 indicates that the FR 500 mg/kg and 1,000 mg/kg body
weight samples had higher NO induction than the SHR control
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Fig. 4. (A) Renin activity, (B) angiotensin I converting enzyme (ACE) inhibitory effects, and (C) angiotensin II levels in the plasma of spontaneously hypertensive rats (SHRs) treated
with ﬁne root concentrate (FR) and hypotensive component-enriched fraction of red ginseng (HCEF-RG) for 8 wk. WKY-control (normal control): WKY provided with sterile distilled
water; SHR-control (hypertension control): SHR provided with sterile distilled water; FR groups (hypertension and FR treatment): SHR orally provided with ﬁne root concentrations
(500 mg/kg, 1,000 mg/kg body weight); HCEF-RG groups (hypertension and HCEF-RG treatment): SHR orally provided with hypotensive components-enriched fraction of red
ginseng (500 mg/kg, 1,000 mg/kg body weight). Values are expressed as mean  SD, n ¼ 8. *p < 0.05 compared with Wistar Kyoto (WKY)-control. **p < 0.05 compared with SHR-
control.
J Ginseng Res 2016;40:237e244242group. The FR 1,000 and HCEF-RG 1,000 groups had signiﬁcantly
(p < 0.05) higher induction of NO than the SHR control group.
Red ginseng activates NO production, which results in a reduc-
tion in the arterial blood pressure [26]. It has previously been
shown that the administration of red ginseng and white ginseng
saponins have hypotensive effects in cat model [27]. Furthermore,
saponins in Korean ginseng have been shown to induce an
endothelium-dependent relaxation effect in rats, increase in cyclic
GMP concentrations in tissues [28], and relaxation of vascular
smooth muscle in the coronary arteries [29]. Thus, total saponins
induce the release of NO from endothelial cells by increasingintracellular entry of Ca2þ, which activates Ca2þ-activated Kþ
channels within the vascular endothelial cell membranes, resulting
in the inﬂux of Ca2þ into endothelial cells and inducing the acti-
vation of endothelial nitric oxide synthase in endothelial cells to
relax blood vessels [30]. In addition, Rg3 has been reported to
suppress platelet aggregation and improve blood circulation [31];
endothelium-dependent relaxation attributable to Rg3 in total sa-
ponins followed a dose-dependent manner [32]. The endothelium-
dependent relaxation potency of Rg3 was found to be 3.4-fold
higher than that of protopanaxatriol ginsenosides, 6.2-fold higher
than that of total saponins, and 79-fold higher than that of Rg1. In
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Fig. 5. Effects of ﬁne root concentrate (FR) and the hypotensive component-enriched fraction of red ginseng (HCEF-RG) on plasma nitric oxide levels after oral administration in
spontaneously hypertensive rats (SHRs) for 8 wk. WKY-control (normal control): WKY provided with sterile distilled water; SHR-control (hypertension control): SHR provided with
sterile distilled water; FR groups (hypertension and FR treatment): SHR orally provided with ﬁne root concentrations (500 mg/kg, 1,000 mg/kg body weight); HCEF-RG groups
(hypertension and HCEF-RG treatment): SHR orally provided with hypotensive components-enriched fraction of red ginseng (500 mg/kg, 1,000 mg/kg body weight). Values are
expressed as mean  SD, n ¼ 8. *p < 0.05 compared with Wistar Kyoto (WKY)-control. **p < 0.05 compared with SHR-control.
K.H. Lee et al / Antihypertensive effect of Rg3 243renovascular hypertensive rats, 100 mg/kg intravenous Korean
ginseng saponins and nonsaponins, respectively, induced a
29  7 mmHg and 11  3 mmHg decrease in blood pressure, which
was highly signiﬁcant (p < 0.01). This reduction in blood pressure
may be attributable to an increase in blood NO caused by an in-
crease in the activity of NO synthase [33]. As a result, in this study,
the administration of 1,000 mg/kg Rg3-Arg-Fru-enriched HCEF-RG
to SHRs, which was equivalent to 4.04 mg/kg Rg3 and 4.48 mg/kg
Arg-Fru, resulted in a 52% increase in NO production and decrease
in blood pressure.
In conclusion, HCEF-RG was successfully prepared by
persimmon vinegar treatment (12 times against ﬁne root concen-
trates, v/v) at 80C for 18 h. Systolic blood pressure and diastolic
blood pressure in the SHR groups treated with HCEF-RG decreased
signiﬁcantly, compared with the SHR control group (p < 0.05). The
SHR groups with HCEF-RG showed decreased activity in rennin and
ACE and reduced angiotensin II levels. Moreover, the SHR group
treated using HCEF-RG of 1,000 mg/kg body weight exhibited the
highest NO concentration among SHR groups (p < 0.05). Therefore,
the results indicate that HCEF-RG has great potential to be used as a
new material for functional food applications and can have a sig-
niﬁcant effect on improving hypertensive conditions.
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